Darovasertib-Crizotinib Combination Achieves Breakthrough Efficacy in Metastatic Eye Cancer

IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal melanoma. According to BioSpace.com, the…

Continue Reading Darovasertib-Crizotinib Combination Achieves Breakthrough Efficacy in Metastatic Eye Cancer